Scarica l'app Stockscreener
13.29
3.13%
-0.43
Dopo l'orario di chiusura:
13.29
Precedente Chiudi:
$13.72
Aprire:
$13.67
Volume 24 ore:
678.50K
Relative Volume:
0.70
Capitalizzazione di mercato:
$1.18B
Reddito:
$17.49M
Utile/perdita netta:
$-78.50M
Rapporto P/E:
-11.07
EPS:
-1.2
Flusso di cassa netto:
$-52.85M
1 W Prestazione:
-3.90%
1M Prestazione:
-12.10%
6M Prestazione:
+19.84%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$13.11
$13.87
Intervallo di 1 settimana:
$13.11
$14.06
Portata 52W:
$8.26
$16.81
Liquidia Corp Stock (LQDA) Company Profile
Nome
Liquidia Corp
Settore
Industria
Telefono
919.328.4400
Indirizzo
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Confronta LQDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
13.29 | 1.18B | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-16 | Iniziato | Raymond James | Outperform |
| 2024-06-25 | Iniziato | Oppenheimer | Perform |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2022-09-19 | Ripresa | Wedbush | Underperform |
| 2022-09-01 | Downgrade | Wedbush | Neutral → Underperform |
| 2022-07-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-05-31 | Iniziato | BTIG Research | Buy |
| 2022-05-26 | Iniziato | BofA Securities | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-05 | Iniziato | Wedbush | Outperform |
| 2018-08-20 | Iniziato | Jefferies | Buy |
| 2018-08-20 | Iniziato | Needham | Buy |
Mostra tutto
Liquidia Corp Borsa (LQDA) Ultime notizie
Liquidia Sues UTC Seeking Patent Damages for Tyvaso DPI Sales - Bloomberg Law News
Liquidia Corp’s chief medical officer sells $50,398 in stock By Investing.com - Investing.com Canada
Liquidia Corp Executives Sell Shares Under Rule 10b5-1 Plan - TradingView
Liquidia Corp’s chief medical officer sells $50,398 in stock - Investing.com
Liquidia Corp’s chief business officer Jason Adair sells shares worth $25,185 - Investing.com India
Great week for Liquidia Corporation (NASDAQ:LQDA) institutional investors after losing 1.5% over the previous year - Yahoo Finance
Breaking Down Liquidia: 4 Analysts Share Their Views - Benzinga
Liquidia at Needham Conference: Strategic Insights on Eutropia Launch - Investing.com Australia
Liquidia at Needham Conference: Strategic Insights on Eutropia Launch By Investing.com - Investing.com India
Liquidia: United Therapeutics Has The Last Laugh (LQDA) - Seeking Alpha
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Liquidia (NASDAQ:LQDA) - Defense World
UPDATELiquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - Yahoo Finance
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Liquidia Technologies (LQDA) Receives a Buy from Scotiabank - The Globe and Mail
Liquidia Co. (NASDAQ:LQDA) Receives $26.63 Average Price Target from Analysts - The AM Reporter
Liquidia says its request for Yutrepia final approval undergoes FDA review - MSN
Liquidia stock rises as Yutrepia undergoes FDA review (LQDA) - Seeking Alpha
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder - Investing.com
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA - TipRanks
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder By Investing.com - Investing.com Canada
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder - The Manila Times
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
Liquidia Corporation (NASDAQ:LQDA) Q4 2024 Earnings Call Transcript - Insider Monkey
Liquidia (NASDAQ:LQDA) Price Target Raised to $34.00 - Defense World
Earnings To Watch: Liquidia Corp (LQDA) Reports Q4 2024 Result - GuruFocus.com
Scotiabank raises Liquidia stock target to $34 on Yutrepia prospects By Investing.com - Investing.com South Africa
What 4 Analyst Ratings Have To Say About Liquidia - Benzinga
Scotiabank raises Liquidia stock target to $34 on Yutrepia prospects - Investing.com
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Raymond James maintains strong buy on Liquidia stock, $27 target - Investing.com
H.C. Wainwright maintains Buy on Liquidia stock, $29 target - Investing.com
Raymond James maintains strong buy on Liquidia stock, $27 target By Investing.com - Investing.com UK
Liquidia Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Liquidia Corp (LQDA) - GuruFocus
Earnings call transcript: Liquidia Technologies Q4 2024 misses revenue forecast - Investing.com
Liquidia Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Liquidia Corp Reports Annual EPS of -$1.66 and Revenue of $14.0 Million, Missing Estimates - GuruFocus.com
Liquidia Corp SEC 10-K Report - TradingView
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update - TradingView
Liquidia Technologies earnings missed by $0.07, revenue fell short of estimates - Investing.com
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million - The Manila Times
When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable? - Simply Wall St
Commit To Buy Liquidia At $7.50, Earn 11.3% Using Options - Nasdaq
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 - The Manila Times
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 - GlobeNewswire Inc.
Insider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA) - GuruFocus.com
Liquidia (LQDA) to Release Earnings on Wednesday - The AM Reporter
Liquidia’s chief commercial officer sells shares worth $9,146 By Investing.com - Investing.com Canada
Liquidia Corp Azioni (LQDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):